The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Learn more about our recent activities to ensure equitable access to COVID-19 medical tools here, and follow us and our team of experts on Twitter for more news on upcoming diagnostics, treatments and vaccines.
MSF developed a briefing document to provide background information for decision-makers regarding the COVID-19 agenda item at the 73rd WHA. MSF recommends the following actions to ensure access and equitable allocation of COVID-19 medical tools:
Adopt binding and enforceable measures
Encourage Member States to explore and use fully the existing policy and legal measures, including flexibilities under the TRIPS Agreement and the Doha Declaration on TRIPS and Public Health
Ensure full transparency of all R&D funding agreements with explicit and binding obligations